Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a potato starch shake off Drug-Resistant gut bacteria?

NCT ID NCT07792915

Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether a dietary fiber called resistant potato starch can reduce the amount of drug-resistant bacteria living in the gut. The study enrolls Veterans who carry these bacteria without symptoms, and half will take the starch daily while the other half takes a placebo. Researchers will measure changes in gut bacteria and markers of gut health. If the starch works, it could offer a simple way to lower the risk of future infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Resistant potato starch (a dietary fiber prebiotic) taken as a powder mixed into food or drinks
What this could lead to
If it works, this could offer a simple, inexpensive way to reduce gut carriage of drug-resistant bacteria, lowering the risk of future infections.
What could go wrong
This is a Phase 2 trial with 120 participants, so results may not apply broadly. The fiber may cause digestive discomfort, and the effect on infection risk is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of C. difficile, Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE), and/or Multi-drug resistant Enterobacteriaceae (MDRE) in the gut as determined by a stool test * Ambulatory/not hospitalized at time of enrollment Exclusion Criteria: * Allergy to any ingredient or source material in intervention or placebo product * Severe gastrointestinal condition that may be exacerbated by high dietary fiber intake (history of bowel obstruction, intestinal strictures, diverticulitis, active inflammatory bowel disease with structuring, gastroparesis, and/or severe gastrointestinal motility disorders) * Uncontrolled diabetes (hospitalized in previous 5 years due to diabetes) * Dysphagia * Fecal microbiome transplant in the last 30 days * Intestinal surgery in the last 30 days * Pregnancy or breastfeeding * Immunosuppression, defined as history of solid organ transplant or as receipt of ablative chemotherapy, steroids at the equivalent of ≥5 mg/day prednisone, antimetabolites, anti-TNF agents, calcineurin inhibitors, or mycophenolate at time of enrollment * Use of probiotics or fiber supplements in previous 30 days * Already on a decolonization protocol * Active infection requiring acute antibiotic treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asymptomatic infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Asymptomatic Infections Clostridium difficile colitis Clostridium infectious disease methicillin-resistant staphylococcus aureus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asymptomatic infections Carbapenem-resistant enterobacteriaceae Clostridium infections Methicillin-resistant staphylococcus aureus (MRSA) Vancomycin-resistant enterococci

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • William S. Middleton Memorial Veterans Hospital, Madison, WI

    Madison, Wisconsin, 53705-2254, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.